<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119196</url>
  </required_header>
  <id_info>
    <org_study_id>100177</org_study_id>
    <nct_id>NCT01119196</nct_id>
  </id_info>
  <brief_title>The Measurement of Insulin Resistance in Peritoneal Dialysis Patients</brief_title>
  <official_title>The Measurement of Insulin Resistance in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to examine the relevance of insulin resistance in peritoneal
      dialysis (PD) patients as well as the means to improve this metabolic derangement. We will do
      so through a prospective randomized study using Icodextrin as an alternate dialysate solution
      to routine glucose-based dialysate. We hypothesize that (1) the glucose loading associated
      with PD leads to impairment in insulin sensitivity, (2) the degree of insulin resistance is
      dependent on the basal metabolic state (fasting versus stimulated), and (3) the replacement
      of conventional dialysate with glucose-sparing dialysate preparations will improve insulin
      resistance and associated metabolic disturbances in PD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in glucose disposal rate</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Pearson or Spearman correlation coefficient values between insulin resistance (IR) measured by insulin clamp study and other methods (e.g., HOMA, QUICKI, OGTT)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>glucose-based dialysate</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>most frequently used Standard of Care (SOC) dialysate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icodextrin dialysate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>alternate SOC dialysate</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Icodextrin dialysate</intervention_name>
    <description>use of alternate SOC dialysate</description>
    <arm_group_label>Icodextrin dialysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable and receiving stable PD for ≥ 3 months;

          -  BMI ≤ 45;

          -  Most recent Kt/V ≥1.7 or Tccr ≥ 50l/week/1.73m2;

          -  On Glucose lactate-buffered PD solutions with consistent glucose exposure.

        Exclusion Criteria:

          -  Pregnancy or breast-feeding;

          -  Intolerance to the study protocols;

          -  Severe, unstable, active, or chronic inflammation disease (active infection, active
             connective tissue disorder, active cancer, HIV, liver disease);

          -  Chronic use of anti-inflammatory medication except low dose (&lt; 10mg/d) prednisone;

          -  Severe hypokalemia (K+ level &lt; 3.0 mEq/L);

          -  Hypercalcemia (Ca++ level &gt; 11.0 mg/dL);

          -  Have a glycogen storage disease;

          -  Intolerant to maltose or isomaltose;

          -  Allergic to cornstarch or icodextrin;

          -  Recent abdominal surgery in the past 30 days;

          -  Chronic Obstructive Lung Disease (COPD) or Interstitial lung disease;

          -  Insulin-Dependent Diabetes Mellitus (IDDM).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alp Ikizler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alp Ikizler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
    <mesh_term>Icodextrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

